Odonate Therapeutics, Inc. (ODT)


-0.05 (-4.27%)

Mr. Kevin Tang
Nasdaq Global Select

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.